Sacubitril/Valsartan: Neprilysin Inhibition 5 Years after PARADIGM-HF (JACC Heart Failure October 2020)

Description

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction, when compared to the gold-standard angiotensin-converting enzyme inhibitor, enalapril.

Editors

Editor-in-Chief
Christopher O’Connor, MD, FACC

Executive Editor
Mona Fiuzat, PharmD, FACC

JACC Heart Failure CME Editors
Tariq Ahmad, MD, MPH
Adam DeVore, MD
Abhinav Sharma, MD
Mitchell Psotka, MD, PhD
Kishan Parikh, MD

Authors
Kieran F. Docherty MBChB
Muthiah Vaduganathan, MD MPH

Important Dates

Date of Release: September 28, 2020
Term of Approval/Date of CME/MOC/ECME Expiration: September 27, 2021

Summary

Availability:

Retired

Cost:

FREE

Credit Offered:

No Credit Offered